Clinical trials: Primary Prevention CVD
Stroke
Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial doppler ultrasonography (TCD) flow velocities…
- Trial name
- NCT00402480
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Duke University
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Women With Breast Cancer
Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer
To develop a method of medical prevention of cardiovascular diseases caused by cardiotoxicity against the background of complex treatment of patients with primary resectable breast cancer to reduce the risk of cardiovascular…
- Trial name
- NCT04588935
- Testing
- Bisoprolol; Perindopril;
- Where
- Belarus
- Volunteers
- 100 people
- Sponsor
- State Institution "Republican Scientific and Practical Center" Cardiology, Belarus
Hereditary Angioedema (HAE)
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
The purpose of this study is to determine if an investigational treatment is safe and well tolerated when administered by intravenous (IV) infusion in Japanese subjects with HAE.
- Trial name
- NCT02865720
- Testing
- CINRYZE 500 U, CINRYZE 1000 U
- Where
- 10 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Shire
Hereditary Angioedema (HAE)
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent angioedema attacks in children 6 to 11 years of…
- Trial name
- NCT02052141
- Testing
- CINRYZE 500, CINRYZE 1000
- Where
- 8 sites in United States, Germany and 3 more
- Volunteers
- 12 people
- Sponsor
- Shire
Cardiovascular Disease, Atrial Fibrillation
Clinical Decision Support for Stroke Prevention in Atrial Fibrillation
A cluster randomised study in the primary care setting to evaluate a electronic clinical decision tool for stroke prophylaxis in patients with atrial fibrillation.
- Conditions
- Cardiovascular Disease, Atrial Fibrillation, Stroke
- Trial name
- CDS-AF (NCT02635685)
- Testing
- Clinical Decision Support tool
- Where
- Sweden
- Volunteers
- 442,105 people
- Sponsor
- University Hospital, Linkoeping
Coronary Heart Disease
Randomized Trial of Behavioral Intervention Versus Standard Treatment
The purpose of this study is to determine the possible preventive effect of behavioural modification versus standard treatment after hospital discharge in CHD patients.
- Trial name
- SUPRIM (NCT00888485)
- Testing
- Behavioral interventional program
- Volunteers
- 362 people
- Sponsor
- Uppsala University
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Hereditary Angioedema (HAE)
Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study
This protocol for post study access allows pediatric participants (2-11 years old at the time of consent) with HAE who have completed study CSL312_3003 (NCT05819775) to continue treatment with CSL312 for routine prevention of HAE…
- Trial name
- NCT07159464
- Testing
- CSL312
- Sponsor
- CSL Behring
Health Risk Appraisal, Heart Disease
Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?
The VA has committed to disseminate a web-based Healthy Living Assessment(HLA) tool and use it as the cornerstone of a personalized prevention plan to engage patients to improve their health behaviors that lead to high health…
- Conditions
- Health Risk Appraisal, Heart Disease, Prevention
- Trial name
- ACTIVATE (NCT01828567)
- Testing
- Shared decision making with a Prevention Coach
- Where
- 2 sites in United States
- Volunteers
- 417 people
- Sponsor
- VA Office of Research and Development
Cardiovascular Diseases, Heart Diseases
Primary Prevention of CHD Risk Factors Occurring in US
To evaluate the effectiveness of primary prevention of coronary heart disease risk factors by examining data from the National Health Examination Survey (NHES) and the National Health and Nutrition Examination Surveys (NHANES) to…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Heart Disease Risk Reduction, Coronary Disease
- Trial name
- NCT00005495
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Prevention, Arterial Hypertension
Possibilities of Perceiving Information on the Primary Prevention of Cardiovascular Diseases in Persons Suffering From Essential Hypertension Through a Social Network
A randomized, prospective study conducted on the basis of a social network (Instagram platform), two-stage. At the first stage, the online school "Save Your Heart" was announced and 945 applicants were enrolled in the training.
- Trial name
- SocialCor (NCT04944472)
- Testing
- HDKQ questionnaire
- Where
- Russia
- Volunteers
- 125 people
- Sponsor
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Obesity, Insulin Resistance
Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)
Animal studies have found that vitamin K-dependent proteins matrix Gla protein and osteocalcin beneficially influence lipid and glucose metabolism, respectively.
- Conditions
- Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases
- Trial name
- NCT02959762
- Testing
- Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Augusta University
Hereditary Angioedema
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
- Trial name
- NCT07654829
- Testing
- KVD900 600 mg
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hereditary Angioedema, HAE
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
- Trial name
- APeX-2 (NCT03485911)
- Testing
- BCX7353 capsules
- Where
- 47 sites in United States, Austria and 9 more
- Volunteers
- 121 people
- Sponsor
- BioCryst Pharmaceuticals
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Hereditary Angioedema
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
The study objective was to evaluate the safety and efficacy of prophylactic use of C1INH-nf for the prevention of acute HAE attacks.
- Trial name
- CHANGE 3 (NCT00462709)
- Testing
- C1 esterase inhibitor [human] (C1INH-nf)
- Where
- 48 sites in United States
- Volunteers
- 146 people
- Sponsor
- Shire
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Hereditary Angioedema, Pediatric
Berotralstat Treatment in Children With Hereditary Angioedema
The purpose of this study is to evaluate the pharmacokinetics (PK), safety and effectiveness of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to < 12 years of age for prophylactic…
- Trial name
- APeX-P (NCT05453968)
- Testing
- Berotralstat
- Where
- 15 sites in Austria, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- BioCryst Pharmaceuticals